Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Cyclophosphamide 9Prednisone 8Doxorubicin 7Vincristine 6Azacitidine 5pembrolizumab 3fludarabine 3belinostat 3Lenalidomide 3Brentuximab Vedotin 310-propargyl-10-deazaaminopterin 3ruxolitinib 2duvelisib 2Gemcitabine 2Dexamethasone 2Biopsy 2Bendamustine Hydrochloride 2venetoclax 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1pomalidomide 1ixazomib 1ivarmacitinib 1daratumumab 1cemiplimab 1calaspargase pegol 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Peripheral × Fenretinide × Clear all
NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡